undamentalytics Newsletter

Aclaris Therapeutics vs Coya Therapeutics

Aclaris Therapeutics and Coya Therapeutics are similar in size: $7.8m and $7.9m of revenue in their latest fiscal years. Coya Therapeutics grew faster (123.6% against -58.2%). Coya Therapeutics kept more of each dollar of sales as profit: a net margin of -267.1% against -829.6%. Aclaris Therapeutics carries less debt relative to equity (0.0% against 0.0%).

Latest fiscal yearAclaris TherapeuticsACRS, 2025Coya TherapeuticsCOYA, 2025
Revenue $7.8m $7.9m
Revenue growth -58.2% 123.6%
Net income −$64.9m −$21.2m
Operating margin -975.9% -283.9%
Net margin -829.6% -267.1%
Return on equity -50.2% -51.4%
Free cash flow −$47.2m —
Cash $20.0m $46.8m
Total debt $0 $0
Debt to equity 0.0% 0.0%
Dividend per share — —
Dividend yield — —
Share buybacks — —
Employees 73 —
Market value $515m $73.5m
Price vs our value range — —
Moat score 14 (Weak) —
Insider trades, 12 months 0 buys, 1 sales 0 buys, 0 sales

Each figure is from the company's latest annual report and links to the page it comes from. Fiscal years can end on different dates. Market value and the value verdict use the delayed price shown on the stock pages. Not a recommendation.

Go deeper

Figures from each company's latest annual report filed with the SEC (10-K or 20-F), as reported, with the fiscal year shown. Not investment advice. How we read filings: methodology.